# Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

> **NCT00263692** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 401 (actual)

## Conditions studied

- Diphtheria
- Acellular Pertussis
- Tetanus

## Interventions

- **BIOLOGICAL:** Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3

## Key facts

- **NCT ID:** NCT00263692
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263692, "Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00263692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*